Rapport Therapeutics shares plunge on stock and convertible bond sales
Rapport Therapeutics shares plunged amid stock and convertible bond sales.
Related stories
Íslandsbanki Reports Third-Quarter 2026 Financial Results
Íslandsbanki reported net profit of ISK 7.3 billion for the third quarter of 2026.
M impact | EQUITY | Oct 29, 2026, 03:46 PM UTC
Cohere Announces Series E Fundraise Targeting CAD $7 Billion
Cohere announced a Series E fundraise targeting CAD $7 billion.
M impact | EQUITY | Oct 29, 2026, 03:45 PM UTC
Forestar Reports Q4 FY26 Net Income of $59.2 Million, Revenue of $580.8 Million
M impact | EQUITY | Oct 29, 2026, 03:45 PM UTC
Íslandsbanki Reports Third-Quarter 2026 Results
Íslandsbanki reported third-quarter 2026 results.
M impact | EQUITY | Oct 29, 2026, 03:45 PM UTC
Hyatt Hotels Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Oct 29, 2026, 03:45 PM UTC
CSW Industrials Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Oct 29, 2026, 03:44 PM UTC